Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GUIDED THERAPEUTICS INCGTHP · Entity 7610 | Director · 10% owner | February 25, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GUIDED THERAPEUTICS INC
Report date February 25, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,391,311 |
Ending reported balance
After 2026-03-26 transaction · row 7
5 source rows · reconciled sequenceRow 1 · 2026-02-25 · Exercise / conversion · Acquired 1,000,000 · Balance 8,924,180 F1: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. Row 2 · 2026-03-26 · Other · Acquired 56,093 · Balance 8,980,273 F4: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773. Row 4 · 2026-03-26 · Other · Acquired 1,040,000 · Balance 10,020,273 F5: On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price. Row 5 · 2026-03-26 · Other · Acquired 19,038 · Balance 10,039,311 F6: These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.2773. Row 7 · 2026-03-26 · Other · Acquired 352,000 · Balance 10,391,311 F7: On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price. |
| Preferred Series F StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-03-26 transaction · row 3
1 source rowRow 3 · 2026-03-26 · Other · Disposed 260 · Balance 0 F5: On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price. |
| Preferred Series F-2 StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-03-26 transaction · row 6
1 source rowRow 6 · 2026-03-26 · Other · Disposed 88 · Balance 0 F7: On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.65 · Expires 2026-09-01 | Direct | 0 |
Reported balance
After 2026-02-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-25 · Disposition to issuer · Disposed 1,000,000 · Balance 0 F1: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.65 · Expires 2027-09-01 | Direct | 1,000,000 |
Reported balance
After 2026-02-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-25 · Grant · Acquired 1,000,000 · Balance 1,000,000 F1: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2026-09-01 | Direct | 0 |
Reported balance
After 2026-02-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-25 · Disposition to issuer · Disposed 1,000,000 · Balance 0 F1: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.20 · Expires 2026-02-25 | Direct | 1,000,000 |
Reported balance
After 2026-02-25 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-02-25 · Grant · Acquired 1,000,000 · Balance 1,000,000 F1: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.20 · Expires 2026-02-25 | Direct | 0 |
Reported balance
After 2026-02-25 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-02-25 · Exercise / conversion · Disposed 1,000,000 · Balance 0 F1: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2026-03-01 | Direct | 2,700,000 |
Reported balance
After 2026-03-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-03-01 · Other · Disposed 900,000 · Balance 2,700,000 F2: 900,000 warrants to purchase shares of common stock with an exercise price of $0.30, with an issuance date of March 1, 2023, expired on March 1, 2026, without being exercised. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2036-03-09 | Direct | 110,000 |
Reported balance
After 2026-03-10 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-03-10 · Grant · Acquired 110,000 · Balance 110,000 F3: One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027.
F2: 900,000 warrants to purchase shares of common stock with an exercise price of $0.30, with an issuance date of March 1, 2023, expired on March 1, 2026, without being exercised.
F3: One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029.
F4: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773.
F5: On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price.
F6: These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.2773.
F7: On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 26, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon Stock | 352,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · nonDerivative · entry 7 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,391,311 F7 · kind: On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price. F7 · price: On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price. Read SEC document |
| March 26, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherPreferred Series F-2 Stock | 88 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · nonDerivative · entry 6 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F7 · kind: On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price. F7 · price: On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price. Read SEC document |
| March 26, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon Stock | 19,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · nonDerivative · entry 5 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,039,311 F6 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.2773. F6 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.2773. Read SEC document |
| March 26, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon Stock | 1,040,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · nonDerivative · entry 4 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,020,273 F5 · kind: On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price. F5 · price: On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price. Read SEC document |
| March 26, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherPreferred Series F Stock | 260 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · nonDerivative · entry 3 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · kind: On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price. F5 · price: On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price. Read SEC document |
| March 26, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon Stock | 56,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · nonDerivative · entry 2 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,980,273 F4 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773. F4 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773. Read SEC document |
| March 10, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | GrantStock Options · Derivative | 110,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · derivative · entry 14 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2036-03-09 F3 · derivative.exercise_date: One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029. Read SEC document |
| March 01, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 900,000 | $0.30 Strike: $0.30 | $270,000.00 |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · derivative · entry 13 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,700,000 Underlying: Common Stock · 900,000 shares Expires 2026-03-01 F2 · kind: 900,000 warrants to purchase shares of common stock with an exercise price of $0.30, with an issuance date of March 1, 2023, expired on March 1, 2026, without being exercised. Read SEC document |
| February 25, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | Exercise / conversionWarrants · Derivative | 1,000,000 | $0.20 Strike: $0.20 | $200,000.00 |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · derivative · entry 12 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2026-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. F1 · price: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. Read SEC document |
| February 25, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | GrantWarrants · Derivative | 1,000,000 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · derivative · entry 11 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2026-02-25 F1 · kind: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. F1 · price: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. Read SEC document |
| February 25, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | Disposition to issuerWarrants · Derivative | 1,000,000 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · derivative · entry 10 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2026-09-01 F1 · kind: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. F1 · price: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. Read SEC document |
| February 25, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | GrantWarrants · Derivative | 1,000,000 | Not disclosed Strike: $0.65 | Not disclosed |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · derivative · entry 9 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2027-09-01 F1 · kind: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. F1 · price: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. Read SEC document |
| February 25, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | Disposition to issuerWarrants · Derivative | 1,000,000 | Not disclosed Strike: $0.65 | Not disclosed |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · derivative · entry 8 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2026-09-01 F1 · kind: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. F1 · price: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. Read SEC document |
| February 25, 2026 Filed May 5, 2026 22:21 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | Exercise / conversionCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-26-002770 · form4.xml · nonDerivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,924,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027. Read SEC document |
| August 21, 2025 Filed Sep 5, 2025 20:03 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon Stock | 932,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-25-006522 · form4.xml · nonDerivative · entry 5 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,924,180 F5 · kind: On August 21, 2025, Mr. Blumberg (WMB Pension Plan fbo Richard Blumberg) converted 233 shares of Series E preferred stock into 932,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 exercise price. F5 · price: On August 21, 2025, Mr. Blumberg (WMB Pension Plan fbo Richard Blumberg) converted 233 shares of Series E preferred stock into 932,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 exercise price. Read SEC document |
| August 21, 2025 Filed Sep 5, 2025 20:03 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherPreferred Series E Stock | 233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-25-006522 · form4.xml · nonDerivative · entry 4 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F5 · kind: On August 21, 2025, Mr. Blumberg (WMB Pension Plan fbo Richard Blumberg) converted 233 shares of Series E preferred stock into 932,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 exercise price. F5 · price: On August 21, 2025, Mr. Blumberg (WMB Pension Plan fbo Richard Blumberg) converted 233 shares of Series E preferred stock into 932,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 exercise price. Read SEC document |
| August 21, 2025 Filed Sep 5, 2025 20:03 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon Stock | 81,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-25-006522 · form4.xml · nonDerivative · entry 3 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,992,180 F4 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.2298. F4 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.2298. Read SEC document |
| June 03, 2025 Filed Sep 5, 2025 20:03 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | GrantStock Options · Derivative | 110,000 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001477932-25-006522 · form4.xml · derivative · entry 6 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2035-06-02 F3 · derivative.exercise_date: One-fourth of the shares are subject to the award vested on June 3, 2025; the remaining shares will vest monthly, starting on September 3, 2025, subject to the reporting person's continued service on each such date, until the award is fully vested on June 2, 2028. Read SEC document |
| April 10, 2025 Filed Sep 5, 2025 20:03 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon Stock | 55,853 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-25-006522 · form4.xml · nonDerivative · entry 2 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,911,059 F2 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.0943. F2 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.0943. Read SEC document |
| April 10, 2025 Filed Sep 5, 2025 20:03 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon Stock | 165,481 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-25-006522 · form4.xml · nonDerivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,855,206 F1 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943. F1 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943. Read SEC document |
| October 14, 2024 Filed Oct 24, 2024 16:10 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon Stock | 400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-006656 · form4.xml · nonDerivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,689,725 F1 · kind: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended on September 30, 2021 and November 11, 2022. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The common stock and warrants from the fourth tranche were issued on September 1, 2024 and October 14, 2024, respectively. F1 · price: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended on September 30, 2021 and November 11, 2022. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The common stock and warrants from the fourth tranche were issued on September 1, 2024 and October 14, 2024, respectively. Read SEC document |
| September 01, 2024 Filed Oct 24, 2024 16:10 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 900,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001477932-24-006656 · form4.xml · derivative · entry 2 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,600,000 Underlying: Common shares · 900,000 shares Expires 2027-09-01 F1 · kind: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended on September 30, 2021 and November 11, 2022. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The common stock and warrants from the fourth tranche were issued on September 1, 2024 and October 14, 2024, respectively. F1 · price: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended on September 30, 2021 and November 11, 2022. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The common stock and warrants from the fourth tranche were issued on September 1, 2024 and October 14, 2024, respectively. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 22:12 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon Stock | 170,563 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-005206 · form4.xml · nonDerivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,289,725 F1 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1093. F1 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1093. Read SEC document |
| July 09, 2024 Filed Sep 4, 2024 23:17 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001477932-24-005518 · form4.xml · derivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 100,000 shares Expires 2034-07-08 F1 · derivative.exercise_date: One-fourth of the shares subject to the award vested on July 9, 2024; the remaining shares will vest monthly, starting on October 9, 2024, subject to the reporting person's continued service on each such date, until the award is fully vested on July 8, 2027. Read SEC document |
| March 26, 2024 Filed Apr 5, 2024 20:46 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon stock | 38,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-001900 · form4.xml · nonDerivative · entry 2 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,119,162 F2 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.1361. F2 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.1361. Read SEC document |
| March 26, 2024 Filed Apr 5, 2024 20:46 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon stock | 114,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-001900 · form4.xml · nonDerivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,080,269 F1 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.1361. F1 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.1361. Read SEC document |
| March 01, 2024 Filed Mar 22, 2024 22:04 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 900,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001477932-24-001435 · form4.xml · derivative · entry 2 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,700,000 Underlying: Common shares · 900,000 shares Expires 2027-03-01 F1 · kind: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended on September 30, 2021 and November 11, 2022. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The third tranche was issued on March 1, 2024 and was due 18 months after the Company obtained the requisite financing. The remaining tranche is due September 2024. F1 · price: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended on September 30, 2021 and November 11, 2022. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The third tranche was issued on March 1, 2024 and was due 18 months after the Company obtained the requisite financing. The remaining tranche is due September 2024. Read SEC document |
| March 01, 2024 Filed Mar 22, 2024 22:04 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon stock | 400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-001435 · form4.xml · nonDerivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,965,357 F1 · kind: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended on September 30, 2021 and November 11, 2022. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The third tranche was issued on March 1, 2024 and was due 18 months after the Company obtained the requisite financing. The remaining tranche is due September 2024. F1 · price: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended on September 30, 2021 and November 11, 2022. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The third tranche was issued on March 1, 2024 and was due 18 months after the Company obtained the requisite financing. The remaining tranche is due September 2024. Read SEC document |
| December 01, 2023 Filed Dec 8, 2023 16:24 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 1,642,500 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001477932-23-009031 · form4.xml · derivative · entry 5 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 1,642,500 shares Expires 2023-12-01 F1 · price: During November 2023, Mr. Blumberg signed an exchange agreement to exchange 1,825,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 1,642,500 warrants to purchase shares of common stock for an exercise price of $0.12. The newly exchanged warrants were subsequently exercised upon payment of $197,100. Read SEC document |
| December 01, 2023 Filed Dec 8, 2023 16:24 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon stock | 1,642,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-23-009031 · form4.xml · nonDerivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,565,357 F1 · price: During November 2023, Mr. Blumberg signed an exchange agreement to exchange 1,825,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 1,642,500 warrants to purchase shares of common stock for an exercise price of $0.12. The newly exchanged warrants were subsequently exercised upon payment of $197,100. Read SEC document |
| November 16, 2023 Filed Dec 8, 2023 16:24 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 1,642,500 | Not disclosed Strike: $0.12 | Not disclosed |
DisclosureSEC source: 0001477932-23-009031 · form4.xml · derivative · entry 4 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,642,500 Underlying: Common shares · 1,642,500 shares Expires 2023-12-01 F1 · kind: During November 2023, Mr. Blumberg signed an exchange agreement to exchange 1,825,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 1,642,500 warrants to purchase shares of common stock for an exercise price of $0.12. The newly exchanged warrants were subsequently exercised upon payment of $197,100. F1 · price: During November 2023, Mr. Blumberg signed an exchange agreement to exchange 1,825,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 1,642,500 warrants to purchase shares of common stock for an exercise price of $0.12. The newly exchanged warrants were subsequently exercised upon payment of $197,100. Read SEC document |
| November 16, 2023 Filed Dec 8, 2023 16:24 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 950,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001477932-23-009031 · form4.xml · derivative · entry 3 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 950,000 shares Expires 2024-01-01 F1 · kind: During November 2023, Mr. Blumberg signed an exchange agreement to exchange 1,825,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 1,642,500 warrants to purchase shares of common stock for an exercise price of $0.12. The newly exchanged warrants were subsequently exercised upon payment of $197,100. F1 · price: During November 2023, Mr. Blumberg signed an exchange agreement to exchange 1,825,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 1,642,500 warrants to purchase shares of common stock for an exercise price of $0.12. The newly exchanged warrants were subsequently exercised upon payment of $197,100. Read SEC document |
| November 16, 2023 Filed Dec 8, 2023 16:24 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 875,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001477932-23-009031 · form4.xml · derivative · entry 2 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 875,000 shares Expires 2023-12-31 F1 · kind: During November 2023, Mr. Blumberg signed an exchange agreement to exchange 1,825,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 1,642,500 warrants to purchase shares of common stock for an exercise price of $0.12. The newly exchanged warrants were subsequently exercised upon payment of $197,100. F1 · price: During November 2023, Mr. Blumberg signed an exchange agreement to exchange 1,825,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 1,642,500 warrants to purchase shares of common stock for an exercise price of $0.12. The newly exchanged warrants were subsequently exercised upon payment of $197,100. Read SEC document |
| September 01, 2023 Filed Sep 20, 2023 21:49 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 900,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001477932-23-006982 · form4.xml · derivative · entry 3 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,800,000 Underlying: Common Shares · 900,000 shares Expires 2026-09-01 F2 · kind: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended during the year ended December 31, 2021. As a result of the consulting agreement Mr.Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The second tranche was issued on September 1, 2023 and was due 12 months after the Company obtained the requisite financing. The remaining two tranches are due in six-month installments until the final tranche is issued in September 2024. F2 · price: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended during the year ended December 31, 2021. As a result of the consulting agreement Mr.Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The second tranche was issued on September 1, 2023 and was due 12 months after the Company obtained the requisite financing. The remaining two tranches are due in six-month installments until the final tranche is issued in September 2024. Read SEC document |
| September 01, 2023 Filed Sep 20, 2023 21:49 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon stock | 400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-23-006982 · form4.xml · nonDerivative · entry 2 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,922,857 F2 · kind: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended during the year ended December 31, 2021. As a result of the consulting agreement Mr.Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The second tranche was issued on September 1, 2023 and was due 12 months after the Company obtained the requisite financing. The remaining two tranches are due in six-month installments until the final tranche is issued in September 2024. F2 · price: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended during the year ended December 31, 2021. As a result of the consulting agreement Mr.Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches. The second tranche was issued on September 1, 2023 and was due 12 months after the Company obtained the requisite financing. The remaining two tranches are due in six-month installments until the final tranche is issued in September 2024. Read SEC document |
| August 21, 2023 Filed Sep 20, 2023 21:49 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon stock | 104,914 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-23-006982 · form4.xml · nonDerivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,522,857 F1 · kind: These shares were issued for payment of accrued dividends on WMB Pension Plan's Series E preferred stock, at a conversion price of $0.1777. WMB Pension Plan is beneficially owned by Rick Blumberg, the reporting individual. F1 · price: These shares were issued for payment of accrued dividends on WMB Pension Plan's Series E preferred stock, at a conversion price of $0.1777. WMB Pension Plan is beneficially owned by Rick Blumberg, the reporting individual. F1 · ownership.nature: These shares were issued for payment of accrued dividends on WMB Pension Plan's Series E preferred stock, at a conversion price of $0.1777. WMB Pension Plan is beneficially owned by Rick Blumberg, the reporting individual. Read SEC document |
| March 31, 2023 Filed Jun 27, 2023 16:02 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon stock | 76,978 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-23-004807 · form4.xml · nonDerivative · entry 3 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,417,943 F3 · kind: These shares were issued for payment of accrued dividends on the reporting individual's Series F and Series F-2 preferred stock, at a conversion price of $0.2712. F3 · price: These shares were issued for payment of accrued dividends on the reporting individual's Series F and Series F-2 preferred stock, at a conversion price of $0.2712. Read SEC document |
| March 15, 2023 Filed Jun 27, 2023 16:02 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon stock | 831,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-23-004807 · form4.xml · nonDerivative · entry 2 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,340,965 F2 · price: During February 2023, Mr. Blumberg signed an exchange agreement to exchange 875,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 831,250 warrants to purchase shares of common stock for an exercise price of $0.20. The newly exchanged warrants were subsequently exercised upon payment of $166,250. Read SEC document |
| March 01, 2023 Filed Jun 27, 2023 16:02 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 900,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001477932-23-004807 · form4.xml · derivative · entry 7 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Shares · 900,000 shares Expires 2026-03-01 F2 · kind: During February 2023, Mr. Blumberg signed an exchange agreement to exchange 875,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 831,250 warrants to purchase shares of common stock for an exercise price of $0.20. The newly exchanged warrants were subsequently exercised upon payment of $166,250. F1 · price: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended during the year ended December 31, 2021. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches, the first of which was issued on March 1, 2023 and was due 6 months after the Company obtained the requisite financing. The remaining tranches are due in six-month installments until the final tranche is issued in September 2024. Read SEC document |
| March 01, 2023 Filed Jun 27, 2023 16:02 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherCommon stock | 400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-23-004807 · form4.xml · nonDerivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,509,715 F1 · kind: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended during the year ended December 31, 2021. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches, the first of which was issued on March 1, 2023 and was due 6 months after the Company obtained the requisite financing. The remaining tranches are due in six-month installments until the final tranche is issued in September 2024. F1 · price: On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg, which was subsequently amended during the year ended December 31, 2021. As a result of the consulting agreement Mr. Blumberg provided $350,000 to the Company in exchange for 1,600,000 common shares and 3,600,000 warrants to acquire common shares with an exercise price of $0.30. Issuance of the common stock and warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The common stock and warrants are required to be issued in four equal tranches, the first of which was issued on March 1, 2023 and was due 6 months after the Company obtained the requisite financing. The remaining tranches are due in six-month installments until the final tranche is issued in September 2024. Read SEC document |
| February 22, 2023 Filed Jun 27, 2023 16:02 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 831,250 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001477932-23-004807 · form4.xml · derivative · entry 6 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 831,250 shares Expires 2023-03-15 F2 · price: During February 2023, Mr. Blumberg signed an exchange agreement to exchange 875,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 831,250 warrants to purchase shares of common stock for an exercise price of $0.20. The newly exchanged warrants were subsequently exercised upon payment of $166,250. Read SEC document |
| February 22, 2023 Filed Jun 27, 2023 16:02 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 831,250 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001477932-23-004807 · form4.xml · derivative · entry 5 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 831,250 Underlying: Common shares · 831,250 shares Expires 2023-03-15 F2 · kind: During February 2023, Mr. Blumberg signed an exchange agreement to exchange 875,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 831,250 warrants to purchase shares of common stock for an exercise price of $0.20. The newly exchanged warrants were subsequently exercised upon payment of $166,250. F2 · price: During February 2023, Mr. Blumberg signed an exchange agreement to exchange 875,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 831,250 warrants to purchase shares of common stock for an exercise price of $0.20. The newly exchanged warrants were subsequently exercised upon payment of $166,250. Read SEC document |
| February 15, 2023 Filed Jun 27, 2023 16:02 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 875,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001477932-23-004807 · form4.xml · derivative · entry 4 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,825,000 Underlying: Common shares · 875,000 shares Expires 2023-02-22 F2 · kind: During February 2023, Mr. Blumberg signed an exchange agreement to exchange 875,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 831,250 warrants to purchase shares of common stock for an exercise price of $0.20. The newly exchanged warrants were subsequently exercised upon payment of $166,250. F2 · price: During February 2023, Mr. Blumberg signed an exchange agreement to exchange 875,000 warrants to purchase shares of common stock for an exercise price of $0.25, for 831,250 warrants to purchase shares of common stock for an exercise price of $0.20. The newly exchanged warrants were subsequently exercised upon payment of $166,250. Read SEC document |
| February 10, 2023 Filed Jun 27, 2023 16:01 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | GrantStock Options · Derivative | 100,000 | Not disclosed Strike: $0.26 | Not disclosed |
DisclosureSEC source: 0001477932-23-004806 · form4.xml · derivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-02-09 F1 · price: One-fourth of the shares subject to the award vested on February 10, 2023; the remaining shares will vest monthly, following 90 days from the grant date, subject to the reporting person's continued service on each such date, until the award is fully vested on February 10, 2026. Read SEC document |
| December 01, 2022 Filed Jun 27, 2023 16:00 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | OtherWarrants · Derivative | 950,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001477932-23-004805 · form4.xml · derivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,700,000 Underlying: Common shares · 950,000 shares Expires 2024-01-01 F1 · kind: On September 30, 2021, the Company entered into a Consulting Agreement with Richard Blumberg pursuant to which the Company agreed to issue 950,000 warrants to purchase an aggregate of 950,000 shares of common stock for $0.25 per share. Issuance of the warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The Company obtained the requisite financing and the warrants were issued on December 1, 2022. The warrants will expire on January 1, 2024 if they are not exercised. F1 · price: On September 30, 2021, the Company entered into a Consulting Agreement with Richard Blumberg pursuant to which the Company agreed to issue 950,000 warrants to purchase an aggregate of 950,000 shares of common stock for $0.25 per share. Issuance of the warrants was predicated on the Company obtaining financing totaling a minimum of $1.0 million and Mr. Blumberg's continued service for the Company. The Company obtained the requisite financing and the warrants were issued on December 1, 2022. The warrants will expire on January 1, 2024 if they are not exercised. Read SEC document |
| September 02, 2022 Filed Jun 27, 2023 15:59 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | PurchaseCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-23-004804 · form4.xml · nonDerivative · entry 1 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,109,715 F1 · price: On September 1, 2022, the Company entered into a Securities Purchase Agreements with Mr. Blumberg pursuant to which the Company issued 1,000,000 shares of its common stock, four-year warrants to purchase an aggregate of 1,000,000 shares of common stock for $0.50 per share and four-year warrants to purchase 1,000,000 shares of common stock for $0.65 per share for an aggregate purchase price of $500,000. Read SEC document |
| September 01, 2022 Filed Jun 27, 2023 15:59 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | PurchaseWarrants · Derivative | 1,000,000 | Not disclosed Strike: $0.65 | Not disclosed |
DisclosureSEC source: 0001477932-23-004804 · form4.xml · derivative · entry 3 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common shares · 1,000,000 shares Expires 2026-09-01 F1 · price: On September 1, 2022, the Company entered into a Securities Purchase Agreements with Mr. Blumberg pursuant to which the Company issued 1,000,000 shares of its common stock, four-year warrants to purchase an aggregate of 1,000,000 shares of common stock for $0.50 per share and four-year warrants to purchase 1,000,000 shares of common stock for $0.65 per share for an aggregate purchase price of $500,000. Read SEC document |
| September 01, 2022 Filed Jun 27, 2023 15:59 UTC | GUIDED THERAPEUTICS INC GTHP · Entity 7610 | PurchaseWarrants · Derivative | 1,000,000 | Not disclosed Strike: $0.50 | Not disclosed |
DisclosureSEC source: 0001477932-23-004804 · form4.xml · derivative · entry 2 Blumberg Richard P. · CIK 0001486345 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common shares · 1,000,000 shares Expires 2026-09-01 F1 · price: On September 1, 2022, the Company entered into a Securities Purchase Agreements with Mr. Blumberg pursuant to which the Company issued 1,000,000 shares of its common stock, four-year warrants to purchase an aggregate of 1,000,000 shares of common stock for $0.50 per share and four-year warrants to purchase 1,000,000 shares of common stock for $0.65 per share for an aggregate purchase price of $500,000. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.